Hernández-Preciado Martha Rocio, Marquez-Pedroza Jazmin, Sánchez-Rosales Nayeli Alejandra, García-Rivera José de Jesús, Kobayashi-Gutiérrez Antonio, Torres-Mendoza Blanca Miriam, Chavarría-Avila Efraín, Montaño-Serrano Raúl Alejandro, Cortes-Enriquez Fernando, Mireles-Ramírez Mario Alberto
High Specialty Medical Unit, Western National Medical Center of the Mexican Institute of Social Security, Guadalajara 44340, Mexico.
Neurosciences Division, Western Biomedical Research Center (IMSS), Guadalajara 44340, Mexico.
J Clin Med. 2022 Jun 22;11(13):3584. doi: 10.3390/jcm11133584.
The objective of this study was to evaluate the clinical files of patients with RRMS who started rituximab (RTX) compared with a second-line treatment (natalizumab (NTZ) or fingolimod (FTY)). This was a historical cohort study. We compared the effect according to the Expanded Disability Status Scale (EDSS) and the number of relapses in RRMS patients receiving these treatments after a mean period of 12 months. We found a statistically significant difference (p < 0.001) when comparing the EDSS scores and the annual relapse rates of patients receiving RTX with those receiving NTZ or FTY. This study is essential for our clinical practice, since patients with limited treatment options represent a challenge with regard to the management of their medical care. However, clinical trials and prospective studies with long follow-up periods are necessary to provide sufficient evidence on the efficacy of RTX and thus include this treatment in the therapeutic profile of patients with MS.
本研究的目的是评估开始使用利妥昔单抗（RTX）的复发缓解型多发性硬化症（RRMS）患者与二线治疗（那他珠单抗（NTZ）或芬戈莫德（FTY））患者的临床档案。这是一项历史性队列研究。我们比较了平均12个月后接受这些治疗的RRMS患者根据扩展残疾状态量表（EDSS）得出的效果以及复发次数。在比较接受RTX治疗的患者与接受NTZ或FTY治疗的患者的EDSS评分和年复发率时，我们发现了具有统计学意义的差异（p < 0.001）。这项研究对我们的临床实践至关重要，因为治疗选择有限的患者在医疗管理方面构成挑战。然而，需要进行长期随访的临床试验和前瞻性研究，以提供关于RTX疗效的充分证据，从而将这种治疗纳入MS患者的治疗方案。
